Mirati Therapeutics, Inc. (NASDAQ:MRTX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

28

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02

Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On May 17, 2017, our Amended and Restated 2013 Equity Incentive
Plan (the 2013 Plan) was amended to, among other things, increase
the aggregate number of shares of common stock authorized for
issuance under the 2013 Plan by 2,900,000 shares.
The foregoing description of the amendment to the 2013 Plan does
not purport to be complete and is qualified in its entirety by
reference to the 2013 Plan, as amended, attached to this Current
Report on Form 8-K as Exhibit 99.1.
Item 5.07
Submission of Matters to a Vote of Security Holders.
Our 2017 Annual Meeting of Stockholders (the “Annual Meeting”)
was held on May 17, 2017. We had 24,939,797>shares of common
stock outstanding and entitled to vote as of March 27, 2017, the
record date for the Annual Meeting. At the Annual Meeting,
14,924,308>shares of common stock were present or represented
by proxy.
At the Annual Meeting, stockholders:
(1) elected Charles M. Baum, M.D., Ph.D.; Bruce L.A. Carter,
Ph.D.; Henry J. Fuchs, M.D.; Michael Grey; Craig Johnson; and
Rodney W. Lappe, Ph.D. as directors to hold office until the 2018
Annual Meeting of Stockholders;
(2) ratified the appointment of Ernst Young LLP as our
independent registered public accounting firm for the fiscal year
ending December 31, 2017; and
(3) approved an amendment to the 2013 Plan to, among other
things, increase the aggregate number of shares of common stock
authorized for issuance under the 2013 Plan by 2,900,000 shares.
The following sets forth detailed information regarding the final
results of the voting for the Annual Meeting:
Proposal 1. Election of Directors
>>

Name
Votes For
Votes Withheld
Broker Non-Votes
Charles M. Baum, M.D., Ph.D.
8,998,335
50,742
5,875,231
Bruce L.A. Carter, Ph.D.
9,008,606
40,471
5,875,231
Henry J. Fuchs, M.D.
7,948,211
1,100,866
5,875,231
Michael Grey
8,965,758
83,319
5,875,231
Craig Johnson
8,248,736
800,341
5,875,231
Rodney W. Lappe, Ph.D.
8,917,823
131,254
5,875,231
Proposal 2. Ratification of the selection of Independent
Registered Public Accounting Firm

Votes For
Votes Against
Abstentions
Broker Non-Votes
14,625,250
288,512
10,546
Proposal 3. Approval of Amendment to 2013 Plan
Votes For
Votes Against
Abstentions
Broker Non-Votes
6,267,287
2,755,821
25,969
5,875,231
Item 9.01
Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Amended and Restated 2013 Equity Incentive Plan, as
amended, and Form of Stock Option Agreement and Form
of Stock Option Grant Notice thereunder.


Mirati Therapeutics, Inc. (NASDAQ:MRTX) Recent Trading Information

Mirati Therapeutics, Inc. (NASDAQ:MRTX) closed its last trading session up +0.05 at 3.65 with 249,804 shares trading hands.

An ad to help with our costs